Tecentriq 1 200 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq placebo
WO42633
Phase 3 small_molecule active
Quick answer
Tecentriq 1 200 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq placebo for Early human epidermal growth factor receptor 2 (HER2) positive breast cancer is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Early human epidermal growth factor receptor 2 (HER2) positive breast cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active